Clinical trials: Remission of Ulcerative Colitis
Prospective Study, Ulcerative Colitis in Remission
A Multicenter Prospective Cohort Study on the Clinical Prognosis of Ulcerative Colitis
Mucosal healing or histological remission is an important target for the treatment of inflammatory bowel disease. In this study, patients with mucosal healing are defined as a control group, observing their clinical outcomes for…
- Trial name
- NCT03698812
- Testing
- Colonoscope
- Where
- China
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Nanfang Hospital, Southern Medical University
Exclusive Enteral Nutrition, Ulcerative Colitis
Combined Application of EEN in the Induction of Remission in PUC
The role of exclusive enteral nutrition (EEN) in the induction of remission in pediatric patients with Crohn's disease had been well documented. But the role of EEN in children with Ulcerative Colitis (UC) was not clear.
- Conditions
- Exclusive Enteral Nutrition, Ulcerative Colitis, Children
- Trial name
- NCT04999241
- Testing
- exclusive enteral nutrition, regular food
- Volunteers
- 40 people
- Sponsor
- Children's Hospital of Fudan University
Ulcerative Colitis, Flare Up, Symptom
Effectiveness of Golimumab in Patients With Ulcerative Colitis: Results of a Real-life Study in Switzerland
TNF inhibitors have improved treatment options for patients with inflammatory bowel disease (IBD) and three TNF inhibitors, infliximab, adalimumab and golimumab are available for treatment of ulcerative colitis in Switzerland.
- Trial name
- NCT05405465
- Testing
- Exposure to golimumab
- Where
- Switzerland
- Volunteers
- 103 people
- Sponsor
- University of Zurich
Ulcerative Colitis (UC)
A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative Colitis
Ulcerative colitis (UC) is a type of inflammatory bowel disease (IBD) characterized by diffuse, continuous inflammation of the colon.
- Trial name
- NCT05316220
- Testing
- Mesalamine
- Where
- 10 sites in United States, Puerto Rico
- Sponsor
- AbbVie
Pediatric Ulcerative Colitis in Remission
Oral Fecal Microbiota Transplantation in Pediatric Ulcerative Colitis
The purpose of this study is to evaluate whether FMT by frozen stool capsules in pediatric UC patients in remission after corticosteroid treatment, can modify their dysbiotic gut microbiota by increasing the richness of their…
- Trial name
- T-FORE (NCT05202990)
- Testing
- Fecal Microbiota Transplantation by Stool capsules, Fecal Microbiota Transplantation by Intra-rectal enemas
- Where
- 3 sites in France
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Ulcerative Colitis
Critical State of "Remission-Recurrence" of Ulcerative Colitis
This study will recruit 100 patients with ulcerative colitis in remission for a 6-month non intervention follow-up observation. During the study, their conditions will be recorded truthfully, including general information…
- Trial name
- CSRRUC (NCT06694883)
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Beijing Hospital of Traditional Chinese Medicine
Ulcerative Colitis
Retarded Phosphatidylcholine Versus Mesalazin in Remission of Ulcerative Colitis.
The purpose of this study is to evaluate if retarded phosphatidylcholine is as effective as mesalazin in preventing an acute episode in ulcerative colitis.
- Trial name
- NCT00259571
- Testing
- retarded release phosphatidylcholine
- Where
- Germany
- Sponsor
- Heidelberg University
Ulcerative Colitis, Ulcerative Colitis Chronic Mild
Combination of Diet and Oral Budesonide for Ulcerative Colitis
The ReDUCE Trial is a multinational single-blinded randomized controlled trial in mild to moderate flare of Ulcerative colitis (UC) disease patients.
- Conditions
- Ulcerative Colitis, Ulcerative Colitis Chronic Mild, Ulcerative Colitis Chronic Moderate
- Trial name
- ReDUCE (NCT05791487)
- Testing
- Ulcerative colitis Exclusion Diet, Partial enteral nutrition (PEN), free diet
- Where
- 6 sites in Israel, Italy and 2 more
- Volunteers
- 90 people
- Sponsor
- Wolfson Medical Center
Inflammatory Bowel Disease, Crohn Disease
Deep Endoscopic Remission Assessed by a Surrogate Biomarker in Patients With Inflammatory Bowel Disease
We hypothesize that the number of needed endoscopic procedure performed at IBD patients (adult and children), can be reduced by using an individualized algorithm of symptoms, blood and faecal biomarkers.
- Conditions
- Inflammatory Bowel Disease, Crohn Disease, Ulcerative Colitis
- Trial name
- NCT01861288
- Where
- Denmark
- Volunteers
- 157 people, healthy volunteers welcome
- Sponsor
- Herlev Hospital
Crohn Disease (CD), Ulcerative Colitis (UC)
Leucine-rich α2-glycoprotein Correlation With Clinical, Endoscopic and Histological Disease Activity of IBD in a EuRopean Context
Prospectively study the correlation between Leucine-rich α2-glycoprotein (LRG) and clinical/endoscopic/histological disease activity in patients with inflammatory bowel disease (IBD) in Europe.
- Trial name
- LEADER (NCT07621783)
- Testing
- Leucine-rich α2-glycoprotein
- Where
- Belgium
- Volunteers
- 100 people
- Sponsor
- Imelda GI Clinical Research Center
Ulcerative Colitis, Flare Up, Symptom
Real-world Data Regarding Treatment of Ulcerative Colitis Patients With Golimumab
TNF inhibitors have improved treatment options for patients with inflammatory bowel disease (IBD) and three TNF inhibitors, infliximab, adalimumab and golimumab are available for treatment of ulcerative colitis in Switzerland.
- Trial name
- NCT03394586
- Testing
- Exposure to golimumab
- Where
- Switzerland
- Volunteers
- 100 people
- Sponsor
- University of Zurich
Ulcerative Colitis
Evaluation of Early Mucosal Healing During Clinical Remission in Pediatric Ulcerative Colitis
Establishing that mucosal healing (MH) has occurred after therapy is an important treatment goal, and the gold standard is endoscopic evaluation. In UC it is unclear if clinical parameters are adequate.
- Trial name
- NCT03179865
- Where
- Israel
- Volunteers
- 28 people
- Sponsor
- Wolfson Medical Center
Ulcerative Colitis, Crohn's Disease
Probiotics in GastroIntestinal Disorders
All of us have millions of bacteria living in our gut. These bacteria are very important to our health providing us with protection against infections of the gut, allowing us to gain extra nutritional value from food we eat and…
- Trial name
- PROGID (NCT00510978)
- Testing
- Bifidobacterium infantis 35624, Lactobacillus salivarius UCC118
- Where
- Ireland
- Volunteers
- 360 people
- Sponsor
- University College Cork
Ulcerative Colitis
Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis
The purpose of this study is to determine whether low dose Asacol® (27 mg/kg - 71 mg/kg) and high dose Asacol® (53 mg/kg - 118 mg/kg) are safe and effective when dosed as 400 mg delayed-release tablets given twice daily for 26…
- Trial name
- CAMPIII (NCT01004185)
- Testing
- Asacol 400 mg
- Where
- 51 sites in United States, Canada and 4 more
- Volunteers
- 39 people
- Sponsor
- Warner Chilcott
Ulcerative Colitis (UC)
Use of the Ulcerative Colitis Diet for Induction of Remission
The goal of the study is to evaluate the use of Ulcerative Colitis Diet for Induction of Remission. The investigators have postulated that we developed could be beneficial for patients with Ulcerative Colitis.
- Trial name
- NCT02217722
- Testing
- Ulcerative Colitis Diet, Antibiotic cocktail
- Where
- Israel
- Volunteers
- 9 people
- Sponsor
- Prof. Arie Levine
Mild to Moderate Ulcerative Colitis
Once Versus Twice Daily Mesalamine to Induce Remission in Pediatric Ulcerative Colitis
The purpose of this study is to evaluate effectiveness of once daily dosing of Pentasa compared with twice daily in children with mild to moderate active ulcerative colitis.
- Trial name
- MUPPIT (NCT01201122)
- Testing
- Mesalamine
- Where
- Israel
- Volunteers
- 86 people
- Sponsor
- Wolfson Medical Center
Ulcerative Colitis, Inflammatory Bowel Diseases
Open Label Study to Assess Safety & Efficacy of QD for Induction of Remission in Pediatric Patients with UC
To date, there are no reports on the use of QD in pediatric patients with UC. There is a great need to increase the repertoire of anti-inflammatory interventions for remission induction, especially in children given the notorious…
- Trial name
- NCT06777706
- Testing
- QD (Qing Dai)
- Where
- 2 sites in Israel
- Volunteers
- 20 people
- Sponsor
- Shaare Zedek Medical Center
Ulcerative Colitis
Combination of Diet and 5ASA ( 5-aminosalicylic Acid) for Ulcerative Colitis
Combination Therapy with Drug and Diet for Induction of Remission in Mild to Moderate Active Pediatric Ulcerative colitis: A Single Blinded, International Randomized Controlled Trial
- Trial name
- INDUCT (NCT03980405)
- Testing
- Group 1- Control Diet, Group 2- UCD Diet
- Where
- Israel
- Volunteers
- 12 people
- Sponsor
- Prof. Arie Levine